AR054336A1 - Tratamiento de enfermedades dermatologicas y del prurito - Google Patents

Tratamiento de enfermedades dermatologicas y del prurito

Info

Publication number
AR054336A1
AR054336A1 ARP060101247A ARP060101247A AR054336A1 AR 054336 A1 AR054336 A1 AR 054336A1 AR P060101247 A ARP060101247 A AR P060101247A AR P060101247 A ARP060101247 A AR P060101247A AR 054336 A1 AR054336 A1 AR 054336A1
Authority
AR
Argentina
Prior art keywords
treatment
dermatological
diseases
tyrosine kinase
prurite
Prior art date
Application number
ARP060101247A
Other languages
English (en)
Inventor
Morten Sloth Weidnerr
Original Assignee
Astion Dev As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Dev As filed Critical Astion Dev As
Publication of AR054336A1 publication Critical patent/AR054336A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Principio para el tratamiento de enfermedades dermatologicas, que comprende inhibir varios pasos cruciales de la cascada inflamatoria, incluyendo por lo menos la inhibicion de la proteína tirosina quinasa SYK, la proteína tirosina quinasa ZAP-70 y la fosfodiesterasa IV (PDE-IV) mediante la administracion por vía sistémica o topica en la piel de una cantidad eficaz de oxaprozina o de un compuesto estrechamente relacionado. La presente es particularmente util para el tratamiento de eczemas, tales como dermatitis de contacto y dermatitis atopica, y para el tratamiento del prurito. La presente también suministra composiciones dermatologicas para usar en el tratamiento de una enfermedad dermatologica.
ARP060101247A 2005-03-30 2006-03-30 Tratamiento de enfermedades dermatologicas y del prurito AR054336A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500437 2005-03-30
DKPA200500438 2005-03-30
DKPA200500948 2005-06-27
DKPA200500949 2005-06-27

Publications (1)

Publication Number Publication Date
AR054336A1 true AR054336A1 (es) 2007-06-20

Family

ID=38218953

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101247A AR054336A1 (es) 2005-03-30 2006-03-30 Tratamiento de enfermedades dermatologicas y del prurito

Country Status (5)

Country Link
US (3) US20060251689A1 (es)
AR (1) AR054336A1 (es)
PE (1) PE20061303A1 (es)
TW (1) TW200722087A (es)
UY (1) UY29449A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
PT3424932T (pt) 2005-02-16 2021-05-19 Anacor Pharmaceuticals Inc Boronoftalidas para utilização terapêutica
CN105949230A (zh) 2005-12-30 2016-09-21 安纳考尔医药公司 含硼的小分子
DK2719388T3 (da) 2006-02-16 2019-05-13 Anacor Pharmaceuticals Inc Borholdige små molekyler som antiinflammatoriske midler
US20080107743A1 (en) * 2006-11-02 2008-05-08 Akpharma Inc. Composition and method for enhancing skin cell growth, proliferation and repair
EP3162787A1 (en) * 2007-03-20 2017-05-03 Evolva, Inc. Compositions comprising 5-epi-beta-vetivone, and its use as a fragrance
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
US9616006B2 (en) 2007-10-10 2017-04-11 DermaMedics, LLC Methods and compositions for treating dermatological diseases and conditions
CA3006143C (en) * 2007-10-10 2021-10-19 Therametics, Llc Methods and compositions for treating dermatological diseases and conditions
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
JP5745279B2 (ja) * 2008-01-09 2015-07-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
DE102008006393A1 (de) * 2008-01-28 2009-07-30 Beiersdorf Ag Verwendung von Lipidkomponenten gegen Pollenallergien
CA2718170A1 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
EP2187893A4 (en) * 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
WO2009140309A2 (en) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
EA201190034A1 (ru) * 2008-12-17 2012-02-28 Анакор Фармасьютикалс, Инк. Полиморфы (s)-3-аминометил-7-(3-гидроксипропокси)-3н-бензо[c][1,2]оксаборол-1-ола
WO2010103116A2 (en) * 2009-03-13 2010-09-16 Dbv Technologies Method of treating eczema
EP2458995A1 (en) * 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
WO2011022337A1 (en) * 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9551710B2 (en) 2010-02-09 2017-01-24 Drexel University Signaling molecule involved in ultraviolet damage to skin
WO2011116348A1 (en) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
IT1406067B1 (it) * 2010-07-14 2014-02-06 Torino Politecnico Composizioni eudermiche.
KR102152901B1 (ko) 2010-09-07 2020-09-07 아나코르 파마슈티칼스 인코포레이티드 세균 감염을 치료하기 위한 벤족사보롤 유도체
CA2991569A1 (en) * 2015-07-08 2017-01-12 Elliptical Therapeutics, Llc Improved topical ketoprofen formulations
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
EP3315488A1 (en) * 2016-10-28 2018-05-02 Elé Corporation Amino acid based amphoteric surfactant
CA3060316A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
KR20200025244A (ko) * 2018-08-29 2020-03-10 연세대학교 산학협력단 푸니칼라진을 포함하는 소양증 예방, 개선 또는 치료용 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32084B1 (en) * 1967-06-07 1973-04-04 Wyeth John & Brother Ltd Thiazole derivatives
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
US4190584A (en) * 1976-08-13 1980-02-26 John Wyeth & Brother Limited Process for preparing oxazoles
IE52909B1 (en) * 1981-04-28 1988-04-13 Wyeth John & Brother Ltd Oxazole derivatives
US4659728A (en) * 1985-02-25 1987-04-21 American Home Products Corporation Hydroxy substituted 4,5-diphenyl-2-oxazole propanoic acid
US4773023A (en) * 1985-04-12 1988-09-20 Giardina Joseph J Apparatus for measuring the rate of heat dissipation
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
JPS63309077A (ja) * 1987-06-11 1988-12-16 Seikosha Co Ltd ビデオプリンタ
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5350769A (en) * 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US6017900A (en) * 1991-07-03 2000-01-25 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and nsaids
EP0608320B1 (en) * 1991-10-16 1998-01-28 Richardson-Vicks, Inc. Enhanced skin penetration system for improved topical delivery of drugs
EG20380A (en) * 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
DE69310518T2 (de) * 1992-07-28 1997-10-02 Procter & Gamble Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US6309630B1 (en) * 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
DE69519055T2 (de) * 1994-06-22 2001-05-31 Canon Kk Träger für die Elektrophotographie, Zwei-Komponenten-Entwickler und Verfahren zur Bildherstellung
US5948416A (en) * 1995-06-29 1999-09-07 The Procter & Gamble Company Stable topical compositions
NZ332861A (en) * 1996-05-20 2000-08-25 G Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
CN1180709A (zh) * 1996-10-21 1998-05-06 湖南医科大学 遗传多发性外生骨疣家族的新多核苷酸和多肽基因
FR2765338B1 (fr) * 1997-06-25 1999-07-23 Inst Francais Du Petrole Dispositif de prelevement et/ou d'injection d'un echantillon de fluide permettant de conserver l'equilibre chimique et/ou thermodynamique
ES2308821T3 (es) * 1997-12-15 2008-12-01 Astellas Pharma Inc. Nuevos derivados de pirimidin-5-carboxamida.
US5984416A (en) * 1998-04-30 1999-11-16 Calvin College Adjustable armrest
US6096896A (en) * 1998-10-15 2000-08-01 Farchemia S.R.L. Process for the preparation of 4.5-diphenyloxazole-2-propanoic acid
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6284802B1 (en) * 1999-04-19 2001-09-04 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue
US20030138399A1 (en) * 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6645520B2 (en) * 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
US20030161867A1 (en) * 2001-05-31 2003-08-28 Lu Guang Wei Skin-permeable selective cyclooxygenase-2 inhibitor composition
JPWO2003024484A1 (ja) * 2001-09-14 2004-12-24 小野薬品工業株式会社 掻痒症治療剤
KR20040072720A (ko) * 2002-01-10 2004-08-18 파마시아 앤드 업존 캄파니 항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 ｃｏｘ-2 억제제의 용도
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
DE60322436D1 (de) * 2002-12-18 2008-09-04 Algorx Verabreichung von capsaicinoiden
EP1572186A2 (en) * 2002-12-19 2005-09-14 Pharmacia Corporation Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
US20040220119A1 (en) * 2003-04-04 2004-11-04 Unigen Pharmaceuticals, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US6852713B2 (en) * 2003-04-16 2005-02-08 Adolor Corporation Lactam derivatives and methods of their use

Also Published As

Publication number Publication date
PE20061303A1 (es) 2006-12-07
UY29449A1 (es) 2006-10-02
TW200722087A (en) 2007-06-16
US20060251689A1 (en) 2006-11-09
US20060229347A1 (en) 2006-10-12
US20060222671A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AR054336A1 (es) Tratamiento de enfermedades dermatologicas y del prurito
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
TN2015000158A1 (en) New indanyloxydihydrobenzofuranylacetic acids
ECSP109882A (es) Derivados de 1-cianociclopropilo como inhibidores de la catepsina k
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
PH12014501697A1 (en) Apoptosis signal-regulating kinase inhibitor
MX2016003582A (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
BRPI0915692B8 (pt) compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2007053844A8 (en) Compositions and methods for treating inflammatory disorders
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
CU20100099A7 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antinflamatorios
PE20142318A1 (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona
CL2007002899A1 (es) Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros.
MX370010B (es) Inhibidores de tirosina cinasa de bruton.
MX2016006744A (es) Inhibidores de tirosina cinasa de bruton.
ECSP077846A (es) Tratamiento de eczemas

Legal Events

Date Code Title Description
FB Suspension of granting procedure